Research

DANZON RECENT RESEARCH 2003-2007

Journal Articles [top]

“Dynamic Competition in Pharmaceuticals: Cross-National Evidence from New Drug Diffusion,” With Ernie Berndt and Greg Kruse, Managerial and Decision Economics forthcoming.

“Mergers and Acquisitions in the Pharmaceutical Industry,” with Sean Nicholson and Andrew J. Epstein. Managerial and Decision Economics forthcoming.

“Vaccine Supply: A Cross-National Perspective.” With Nuno Pereira and Sapna Tejwani. Health Affairs May/June 2005.

“Why Sole Supplier Vaccine Markets May be Here to Stay.” With Nuno Pereira. Health Affairs May/June 2005

“Alternative Strategies for Medicare Payment of Outpatient Prescription Drugs - Part B and Beyond.” With Gail R. Wilensky and Kathleen E. Means. American J. of Managed Care, 11(3): 173-180, 2005.

“The Impact of Price Regulation on the Launch Delay of New Drugs.” With Y. Richard Wang and Liang Wang. Health Economics, 14(3), 2005.

"Productivity in Pharmaceutical-Biotechnology R&D: The Role of Experience and Alliances" With Sean Nicholson and Nuno Sousa Pereira. J. of Health Economics, 24(2): 317-339, 2005.

“Biotech-Pharma Alliances as a Signal of Asset and Firm Quality.” With Sean Nicholson and Jeff McCulloch. J. of Busines July 2005.

"From the Field: Closing the Doughnut Hole: No Easy Answers." Health Affairs Web Exclusive. July 2004. http://content.healthaffairs.org/cgi/reprint/hlthaff.w4.405v1. Last accessed September 22, 2004.

"Prices and Availability of Pharmaceuticals: Evidence From Nine Countries." With Michael F. Furukawa. Health Affairs Web Exclusive. October 2003. http://www.healthaffairs.org/WebExclusives/Danzon_Web_Excl_102903.htm.

"Differential Pricing for Pharmaceuticals: Reconciling Access, R&D, and Patents." With Adrian Towse. International Journal of Health Care Finance and Economics. 3: 183-205, 2003.

“Effects of Tiered Co-Payments for Pharmaceuticals.” With Tom Rector and Mark Pauly. Medical Care, 41(3). March 2003.

Chapters in Books [top]

“Regulation of the Pharmaceutical Industry.” Forthcoming in NBER Survey of Regulation, ed. Nancy Rose.

“Product Development Priorities.” With Adel Mahmoud, John Barton and Roy Mugerwa.” in Disease Control Priorities. Eds. Dean Jamison and Joel Bremen. Institute of Medicine. April 2006

“Theory and Implementation of Differential Pricing for Pharmaceuticals.” With Adrian Towse. In International Public Goods and Transfer of Technology Under a Globalized Intellectual Property Regime. Eds. Keith Maskus and Jerome Reichman Cambridge University Press. Forthcoming 2005.

“The “Crisis” in Medical Malpractice Insurance” with Andrew Epstein and Scott Johnson. In Brookings-Wharton Papers on Financial Services: 2004 , Richard Herring and Robert Litan, eds. Brookings Institution Press. 2004

"Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand." With Jonathan D. Ketcham. In Frontiers in Health Policy Research, Vol. 7, David M. Cutler & Allan M. Garber, eds. National Bureau of Economic Research and MIT Press. 2004.

Working Papers [top]

“Prices and Availability of Biopharmaceuticals.” With Michael Furukawa. Under review at Heath Affairs.

“Crises in Medical Malpractice Insurance: Effects of Price Cutting in the Preceding Soft Market.” With Scott Harrington and Andrew Epstein.

“Exits from Vaccine Markets in the US: The Role of Competition vs. Regulation.” With Nuno Pereira.

“Effects of Regulation on Launch Prices and Launch Lags.” With Andrew Epstein.

Selected Testimony and Invited Speeches [top]

NIH Conference on Assessing the Health Effects of Bioactive Food Components. “Estimating the Economic Contribution of Dietary Components in Managing Health Costs.” March 2005.

NBER Regulation Project. “Regulation of the Pharmaceutical Industry.” Stanford. Feb. 2005.

National Association of Social Insurance. Medicare Modernization Conference. “Drug Reimportation.” Washington DC. Jan 2005.

American Economic Association Meetings. “Dynamic Competition in the Pharmaceutical Industry.” With Ernie Berndt. Jan. 2005.

The Economist Conference on the Pharmaceutical Industry. “Drug Importation: Economic Effects.” November 2004.

Biotech Industry Organization (BIO) Annual Meeting. “Effects of Drug Importation.” San Francisco. June 2004.

Deutsche Bank Annual Health Care Conference. “Drug Pricing and Reimportation.” May 2004.

Other Professional Appointments [top]

• National Institutes of Health, Fogarty International Center Advisory Board, Member, 2004–2008
• National Academies, Policy & Global Affairs Oversight Board, Member, 2004–2007
• California Health Benefits Review Program, National Advisory Board, Member, 2004 to present
• Institute of Medicine, Member 1991 to present
• Institute of Medicine, Board on Global Health, Member, 2000–2004
• Institute of Medicine Committee on Malaria, Member, 2002–2004

Corporate and Other Boards [top]

• Medarex Inc., Director 2005-
• Merck Vaccines Advisory Board, 2003 --
• International Health Economics Association Board 2000–2004
• Office of Health Economics, London, Policy Board 1995 –

Selected Executive Education and Conference Organization [top]

• Wharton Windhover Program for Pharmaceutical Executives, Academic Co-Director, with Roger Longman, The Aresty Institute, May 2004, 2005.
• Wyeth Program on Global Positioning, Nov. 2004; April 2005.
• Aventis Leadership Program, 2004.
• Wharton Windhover Program for Pharmaceutical Executives. Program Co-Director with Roger Longman, The Aresty Institute, 1999–2003.